📊 AURX Key Takeaways
Is Nuo Therapeutics, Inc. (AURX) a Good Investment?
Nuo Therapeutics exhibits severe financial distress with negative stockholders' equity of -$419.6K, indicating the company is technically insolvent. Despite 124.3% revenue growth, the company is burning cash at an alarming rate (-$673.9K free cash flow) while maintaining massive operating losses (-87.4% margin), and with only $514.8K in cash reserves against $2.3M in liabilities, the company faces imminent solvency crisis.
Nuo Therapeutics is showing strong top-line growth and solid gross margins, but the business remains deeply unprofitable with operating and net margins near -87%. Negative equity, limited cash, and ongoing free cash flow burn indicate weak financial resilience, so the recent revenue improvement does not yet translate into durable fundamental strength.
Why Buy Nuo Therapeutics, Inc. Stock? AURX Key Strengths
- Strong revenue growth of 124.3% YoY demonstrates market demand for products
- Gross margin of 69.0% indicates pricing power and product viability at production level
- No long-term debt reduces refinancing risk in near term
- Revenue grew 124.3% year over year, indicating meaningful recent demand improvement
- Gross margin of 69.0% suggests the core product economics can support attractive unit-level profitability
- No long-term debt reduces refinancing and interest burden risk
AURX Stock Risks: Nuo Therapeutics, Inc. Investment Risks
- Negative stockholders' equity of -$419.6K indicates technical insolvency and potential shareholder dilution
- Severe cash burn of -$673.9K FCF with only $514.8K cash on hand provides less than one quarter of runway
- Operating losses of -$1.9M despite revenue growth indicate inability to achieve operational efficiency
- Liabilities of $2.3M exceed total assets of $1.9M by $400K creating balance sheet crisis
- Negative operating cash flow of -$442.3K shows business cannot fund operations internally
- Operating losses remain severe, with operating income of -$1.94M on just $2.22M of revenue
- Negative stockholders equity of -$419.61K reflects a stressed balance sheet and weak capital cushion
- Cash generation is negative, with free cash flow of -$673.88K and only $514.80K of cash on hand
Key Metrics to Watch
- Cash position depletion rate and runway to insolvency
- Operating loss trajectory and path to profitability timeline
- Revenue growth sustainability and gross margin maintenance
- Capital requirements and dilution from equity financing
- Working capital management and accounts payable/receivable trends
- Operating margin improvement toward breakeven
- Cash balance and operating cash flow burn rate
Nuo Therapeutics, Inc. (AURX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Nuo Therapeutics, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
AURX Profit Margin, ROE & Profitability Analysis
AURX vs Healthcare Sector: How Nuo Therapeutics, Inc. Compares
How Nuo Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Nuo Therapeutics, Inc. Stock Overvalued? AURX Valuation Analysis 2026
Based on fundamental analysis, Nuo Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Nuo Therapeutics, Inc. Balance Sheet: AURX Debt, Cash & Liquidity
AURX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Nuo Therapeutics, Inc.'s revenue has grown significantly by 2,167% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.05 indicates the company is currently unprofitable.
AURX Revenue Growth, EPS Growth & YoY Performance
AURX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $371.0K | -$537.9K | $-0.01 |
| Q2 2025 | $364.8K | -$540.1K | $-0.01 |
| Q1 2025 | $234.6K | -$708.8K | $-0.02 |
| Q3 2024 | $232.2K | -$540.1K | $-0.01 |
| Q2 2024 | $118.2K | -$540.1K | $-0.01 |
| Q1 2024 | $61.1K | -$708.8K | $-0.02 |
| Q3 2023 | $38.3K | -$375.4K | $-0.02 |
| Q2 2023 | N/A | -$375.4K | $-0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Nuo Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
AURX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Nuo Therapeutics, Inc. (CIK: 0001091596)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AURX
What is the AI rating for AURX?
Nuo Therapeutics, Inc. (AURX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 91% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AURX's key strengths?
Claude: Strong revenue growth of 124.3% YoY demonstrates market demand for products. Gross margin of 69.0% indicates pricing power and product viability at production level. ChatGPT: Revenue grew 124.3% year over year, indicating meaningful recent demand improvement. Gross margin of 69.0% suggests the core product economics can support attractive unit-level profitability.
What are the risks of investing in AURX?
Claude: Negative stockholders' equity of -$419.6K indicates technical insolvency and potential shareholder dilution. Severe cash burn of -$673.9K FCF with only $514.8K cash on hand provides less than one quarter of runway. ChatGPT: Operating losses remain severe, with operating income of -$1.94M on just $2.22M of revenue. Negative stockholders equity of -$419.61K reflects a stressed balance sheet and weak capital cushion.
What is AURX's revenue and growth?
Nuo Therapeutics, Inc. reported revenue of $2.2M.
Does AURX pay dividends?
Nuo Therapeutics, Inc. does not currently pay dividends.
Where can I find AURX SEC filings?
Official SEC filings for Nuo Therapeutics, Inc. (CIK: 0001091596) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AURX's EPS?
Nuo Therapeutics, Inc. has a diluted EPS of $-0.03.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is AURX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Nuo Therapeutics, Inc. has a STRONG SELL rating with 91% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is AURX stock overvalued or undervalued?
Valuation metrics for AURX: ROE of N/A (sector avg: 15%), net margin of -87.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy AURX stock in 2026?
Our dual AI analysis gives Nuo Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AURX's free cash flow?
Nuo Therapeutics, Inc.'s operating cash flow is $-442.3K, with capital expenditures of $231.6K. FCF margin is -30.4%.
How does AURX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -87.2% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.16 (avg: 2).